Krisann Schulz
Physician Assistant · Plainview, TXNPI 1528363900
Payments from drug & device makers
Across 81 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$409
- Exeltis, USA Inc.$321
- Merck$242
- AbbVie$158
- Pfizer$123
- Novo Nordisk$101
- plus $356 from 14 others
What the payments were for
- Food & beverage$1,709100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $409 |
| Exeltis, USA Inc. | 1 | $321 |
| Merck | 17 | $242 |
| AbbVie | 9 | $158 |
| Pfizer | 4 | $123 |
| Novo Nordisk | 6 | $101 |
| Lilly USA, LLC | 5 | $69 |
| Sanofi-aventis U.S. LLC | 4 | $57 |
| Abbott | 2 | $34 |
| Exact Sciences | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Inogen, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Bayer | 1 | $15 |
| GSK | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Amgen | 1 | $12 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Slynd$321
How this compares
$1,709 in reported general payments places this provider in the 70th percentile of 8,308 physician assistant providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 13 | $63,364 |
| OzempicSemaglutide | 20 | $22,338 |
| EliquisApixaban | 20 | $21,279 |
| MounjaroTirzepatide | 15 | $16,001 |
| XareltoRivaroxaban | 22 | $14,843 |
| JanuviaSitagliptin Phosphate | 12 | $11,630 |
| FarxigaDapagliflozin Propanediol | 13 | $10,474 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,596 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,502 |
| Levothyroxine Sodium | 221 | $1,354 |
| Ventolin HfaAlbuterol Sulfate | 22 | $1,304 |
| Gabapentin | 69 | $1,229 |
| Omeprazole | 100 | $1,068 |
| Memantine Hcl | 53 | $929 |
| Potassium Chloride | 95 | $927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $12 | $63,36413 claims |
| Novo NordiskOzempic | $101 | $22,33820 claims |
| PfizerEliquis | $123 | $21,27920 claims |
| Lilly USA, LLCMounjaro | $69 | $16,00115 claims |
| AstraZenecaFarxiga, Symbicort | $409 | $14,06926 claims |
| MerckJanuvia | $242 | $11,63012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Plainview
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.